Canaccord Genuity Analysts Give Endo International PLC (ENDP) a $14.00 Price Target

Canaccord Genuity set a $14.00 price target on Endo International PLC (NASDAQ:ENDP) in a research note published on Thursday, May 11th. The firm currently has a hold rating on the stock.

Several other equities research analysts have also commented on ENDP. Royal Bank of Canada set a $15.00 price target on Endo International PLC and gave the stock a hold rating in a research note on Saturday, April 8th. Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a research note on Wednesday, March 1st. Susquehanna Bancshares Inc upgraded Endo International PLC from a neutral rating to a positive rating in a research note on Tuesday, January 31st. Vetr lowered Endo International PLC from a strong-buy rating to a hold rating and set a $11.34 price target for the company. in a research note on Thursday, April 27th. Finally, Mizuho dropped their price target on Endo International PLC from $25.00 to $15.00 and set a buy rating for the company in a research note on Tuesday, January 31st. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $18.74.

Endo International PLC (NASDAQ ENDP) opened at 10.77 on Thursday. The stock’s 50 day moving average price is $12.25 and its 200 day moving average price is $12.75. Endo International PLC has a 12-month low of $9.70 and a 12-month high of $24.93. The stock’s market cap is $2.40 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The firm’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.08 earnings per share. Analysts forecast that Endo International PLC will post $3.58 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Canaccord Genuity Analysts Give Endo International PLC (ENDP) a $14.00 Price Target” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/06/17/endo-international-plc-endp-given-a-14-00-price-target-at-canaccord-genuity-updated-2-updated-updated.html.

Several hedge funds have recently made changes to their positions in ENDP. Macquarie Group Ltd. increased its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares during the period. Point View Wealth Management Inc. increased its stake in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares during the period. Acrospire Investment Management LLC increased its stake in shares of Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock valued at $159,000 after buying an additional 4,597 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Endo International PLC during the fourth quarter valued at about $213,000. Finally, Capital Fund Management S.A. bought a new stake in shares of Endo International PLC during the first quarter valued at about $260,000. 93.28% of the stock is currently owned by institutional investors and hedge funds.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

What are top analysts saying about Endo International PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit